SCHEMBL1022151

SCHEMBL1022151

CCC(=O)C(C)(C)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.42
ALDH1A1 P00352 3/20 0.40
TSHR P16473 2/20 0.40
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
TDP1 Q9NUW8 2/20 0.35
HMGCR P04035 1/20 0.33
CHRM1 P11229 1/20 0.33
TBXA2R P21731 1/20 0.33
ADRA1A P35348 1/20 0.33
KDM4C Q9H3R0 1/20 0.32
DRD2 P14416 1/20 0.31
OPRM1 P35372 1/20 0.31
DRD3 P35462 1/20 0.31
TET2 Q6N021 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC8 Q9BY41 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216131 0.97 FFAR3 (0.40) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL4841349 0.87 FFAR3 (0.36) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL6011032 0.85 FFAR3 (0.35) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL2545646 0.84 ALDH1A1 (0.41) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
Acetoacetic Acid SCHEMBL4622738 0.84 FFAR3 (0.36) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL5547489 0.79 TDP1 (0.41) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL7454835 0.78 HDAC3 (0.46) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL18125736 0.77 TSHR (0.40) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL911270 0.77 FFAR3 (0.42) FFAR3ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL4140338 0.77 TDP1 (0.42) FFAR3ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4077273-B1 ALDIMINES AND USES THEREOF BOSTIK SA (FR) 2025-04-02 EP disclosed
US-20230400766-A1 ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-12-14 US disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 US disclosed
EP-4077446-B1 POLYIMINES AND USES THEREOF BOSTIK SA (FR) 2023-08-23 EP disclosed
CN-116589375-A Alcohol derivatives as Kv7 potassium channel openers H.隆德贝克有限公司 2023-08-15 CN disclosed
CN-111727182-B Alcohol derivatives as Kv7 potassium channel openers H.隆德贝克有限公司 2023-05-26 CN disclosed
EP-4077446-A1 POLYIMINES AND USES THEREOF Bostik SA (FR) 2022-10-26 EP disclosed
EP-4077273-A1 ALDIMINES AND USES THEREOF Bostik SA (FR) 2022-10-26 EP disclosed
CN-114206328-A Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures H.隆德贝克有限公司 2022-03-18 CN disclosed
WO-2021122595-A1 POLYIMINES AND USES THEREOF BOSTIK SA (FR) 2021-06-24 WO disclosed
EP-1645657-A1 METHOD FOR FORMING THIN FILM AND BASE HAVING THIN FILM FORMED BY SUCH METHOD KONICA MINOLTA HOLDINGS, INC. (JP) 2006-04-12 EP disclosed
EP-0558603-B1 RETROVIRAL PROTEASE INHIBITORS MONSANTO CO (US) 1998-08-26 EP disclosed
US-5698569-A Retroviral protease inhibitors G. D. SEARLE & CO. (US) 1997-12-16 US disclosed
US-5622949-A AIDS THERAPY G. D. SEARLE & CO. (US) 1997-04-22 US disclosed
US-5620977-A HUMAN IMMUNODEFICIENCY VIRUS G.D. SEARLE & CO. (US) 1997-04-15 US disclosed
US-5614522-A SULFONAMIDE AND UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS G.D. SEARLE & CO. (US) 1997-03-25 US disclosed
EP-0558673-B1 RETROVIRAL PROTEASE INHIBITORS MONSANTO CO (US) 1996-04-17 EP disclosed
US-5475013-A Inhibit human immunodeficiency virus protease MONSANTO COMPANY (US) 1995-12-12 US disclosed
EP-0513285-A1 IMIDAZOL-2-YL DERIVATIVES OF SUBSTITUTED BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION. ERBA CARLO SPA (IT) 1992-11-19 EP disclosed
CN-1031533-A Stable 1-Oxapenem-3-carboxylic acid BAYER AG (DE) 1989-03-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR FFAR3 61/4885ALDH1A1 3305/4885TSHR 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.